BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dolinger MT, Rolfes P, Phan BL, Dubinsky MC. Letter: tofacitinib use for biologic-refractory paediatric inflammatory bowel disease. Aliment Pharmacol Ther 2019;50:966-7. [DOI: 10.1111/apt.15496] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Mishra S, Jena A, Kakadiya R, Sharma V, Ahuja V. Positioning of tofacitinib in treatment of ulcerative colitis: a global perspective. Expert Review of Gastroenterology & Hepatology. [DOI: 10.1080/17474124.2022.2106216] [Reference Citation Analysis]
2 Bandeira A, Albino-Teixeira A, Magina S. Systematic review - alopecia areata and tofacitinib in paediatric patients. Cutan Ocul Toxicol 2022;:1-8. [PMID: 35687530 DOI: 10.1080/15569527.2022.2084622] [Reference Citation Analysis]
3 Alajmi R, Alabdulhadi M, Alali AA, Shehab M. Tofacitinib for a Child with Refractory Steroid-Dependent Ulcerative Colitis: A Case Report and Review of the Literature. Am J Case Rep 2021;22:e934460. [PMID: 34767543 DOI: 10.12659/AJCR.934460] [Reference Citation Analysis]
4 Geem D, Kugathasan S. It Takes Two to Make It Right: Dual Biologic and Small Molecule Therapy for Treatment-Refractory Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis 2021;27:1361-2. [PMID: 33200791 DOI: 10.1093/ibd/izaa279] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Llano EM, Shrestha S, Burstein E, Boktor M, Fudman DI. Favorable Outcomes Combining Vedolizumab With Other Biologics or Tofacitinib for Treatment of Inflammatory Bowel Disease. Crohn's & Colitis 360 2021;3:otab030. [DOI: 10.1093/crocol/otab030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Moore H, Dubes L, Fusillo S, Baldassano R, Stein R. Tofacitinib Therapy in Children and Young Adults With Pediatric-onset Medically Refractory Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2021;73:e57-62. [PMID: 34091545 DOI: 10.1097/MPG.0000000000003190] [Reference Citation Analysis]
7 Dolinger MT, Spencer EA, Lai J, Dunkin D, Dubinsky MC. Dual Biologic and Small Molecule Therapy for the Treatment of Refractory Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis 2021;27:1210-4. [PMID: 33125058 DOI: 10.1093/ibd/izaa277] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
8 Steinberg JM, Charabaty A. The Management Approach to the Adolescent IBD Patient: Health Maintenance and Medication Considerations. Curr Gastroenterol Rep 2020;22:5. [PMID: 31997099 DOI: 10.1007/s11894-019-0739-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]